International collaboration is crucial for enhancing rural cancer care, with shared experiences and solutions from across the ...
The combination of alnodesertib and irinotecan shows promising efficacy in ATM-negative metastatic colorectal cancer, with a ...
During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.
The FDA has cleared a phase 3 trial for lacutamab in CTCL, following promising phase 2 results showing durable activity and safety. TELLOMAK 3 will assess progression-free survival with two cohorts: ...
The FDA approves a new diagnostic tool enhancing precision treatment for advanced endometrial carcinoma, improving patient outcomes with targeted therapies. The FDA has approved the OncoMate® MSI Dx ...
The investigational, potentially first-in-class agent tinostamustine (EDO-S101) has earned FDA orphan drug designation (ODD) ...
The FDA has granted fast track designation to the EGFR/HER3 bispecific antibody-drug conjugate (ADC) AVZO-1418 for treatment ...
In terms of prognostic risk factors, HER2 positivity, BM surgical resection, and diagnosis after 2014 were associated with ...
The triplet therapy was effective only in patients with nonmutated PIK3CA and ESR1 genes, achieving a median PFS of 9.1 ...
El-Khoueiry, MD, discussed nivolumab plus ipilimumab vs lenvatinib/sorafenib in unresectable HCC. Immunotherapy has become a ...
Significant progress in bispecific antibodies, antibody-drug conjugates, and radiopharmaceuticals has been achieved this year ...
In patients with metastatic breast cancer, pre-treatment interstitial lung abnormalities (ILAs) and human epidermal growth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback